Striking study results last year indicated a new type of medicine may improve on Merck’s immunotherapy, spurring a wave of ...
1). It is now well established that antibodies that block the interaction between PD-1 on T cells and PD-L1 on tumor cells can boost T cell activity and proliferation, leading to enhanced ...
Researchers have discovered a strong association between the use of immune checkpoint inhibitors for cancer treatment and a ...
Top-line Phase 2/3 data readout for COMPANION-002, evaluating tovecimig (CTX-009 - a DLL4 x VEGF-A bispecific antibody) in patients with biliary ...
L-type calcium channel blockers reduce PD risk... These pharmacological properties of dihydropyridine-class calcium channel blockers were evident in the Ritz et al. study. By documenting the use ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback